News & Updates
Filter by Specialty:
Does race/ethnicity affect the safety, efficacy of semaglutide?
A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.
Does race/ethnicity affect the safety, efficacy of semaglutide?
29 Jul 2024
Study presents alternate treatment approach for EARLY T2D
In the EARLY* trial, a 16-week intervention consisting of a 5:2 intermittent fasting meal replacement (5:2 MR) diet trumps two antidiabetic agents in improving glycaemic control and weight loss, as well as BP, TG, and HDL-C** levels in overweight or obese Chinese individuals with newly diagnosed type 2 diabetes (T2D).
Study presents alternate treatment approach for EARLY T2D
29 Jul 2024
Disrupted circadian rhythm a modifiable risk factor for Alzheimer’s disease?
Circadian rhythm disruption appears to precede the accumulation of amyloid-beta plaques and potentially represents a modifiable risk factor for Alzheimer's disease (AD), according to a study.
Disrupted circadian rhythm a modifiable risk factor for Alzheimer’s disease?
28 Jul 2024
Vibegron relieves OAB symptoms in men treated for BPH
Treatment with vibegron significantly improves overactive bladder (OAB) symptoms in men who are being treated for benign prostatic hyperplasia (BPH), including daily micturitions and urgency episodes, results from the phase III COURAGE trial have shown. It is well tolerated and has an acceptable safety profile, with adverse event (AE) rates similar to placebo.